MA49846B1 - Anticorps liant egfr et cmet - Google Patents

Anticorps liant egfr et cmet

Info

Publication number
MA49846B1
MA49846B1 MA49846A MA49846A MA49846B1 MA 49846 B1 MA49846 B1 MA 49846B1 MA 49846 A MA49846 A MA 49846A MA 49846 A MA49846 A MA 49846A MA 49846 B1 MA49846 B1 MA 49846B1
Authority
MA
Morocco
Prior art keywords
antibody
cmet
bind
variable domain
egfr
Prior art date
Application number
MA49846A
Other languages
English (en)
Other versions
MA49846A (fr
Inventor
Mark Throsby
Ton Logtenberg
Cecilia Anna Wilhelmina Geuijen
Robertus Cornelis ROOVERS
Cornelis Adriaan De Kruif
Original Assignee
Merus N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus N.V. filed Critical Merus N.V.
Publication of MA49846A publication Critical patent/MA49846A/fr
Publication of MA49846B1 publication Critical patent/MA49846B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des anticorps bispécifiques qui comprennent un premier domaine variable qui peut se lier à une partie extracellulaire du récepteur du facteur de croissance épidermique (EGFR) et un second domaine variable qui peut se lier à une partie extracellulaire du proto-oncogène MET, la tyrosine kinase réceptrice (cMET). L'anticorps peut comprendre une chaîne légère commune, peut être un anticorps humain, ou un anticorps pleine longueur. Dans certains modes de réalisation, l'anticorps bispécifique est un anticorps au format IgGl ayant une stœchiométrie anti-EGFR, anti-cMET de 1:1, dans d'autres, l'anticorps a un domaine variable qui peut se lier à l'EGFR et un domaine variable qui peut se lier à cMET.
MA49846A 2017-08-09 2018-08-09 Anticorps liant egfr et cmet MA49846B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17185572 2017-08-09
PCT/NL2018/050537 WO2019031965A1 (fr) 2017-08-09 2018-08-09 Anticorps qui se lient à l'egfr et à cmet
EP18766377.8A EP3665198B9 (fr) 2017-08-09 2018-08-09 Anticorps liant egfr et cmet

Publications (2)

Publication Number Publication Date
MA49846A MA49846A (fr) 2020-06-17
MA49846B1 true MA49846B1 (fr) 2025-05-30

Family

ID=59579503

Family Applications (2)

Application Number Title Priority Date Filing Date
MA71419A MA71419A (fr) 2017-08-09 2018-08-09 Anticorps se liant à egfr et cmet
MA49846A MA49846B1 (fr) 2017-08-09 2018-08-09 Anticorps liant egfr et cmet

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA71419A MA71419A (fr) 2017-08-09 2018-08-09 Anticorps se liant à egfr et cmet

Country Status (27)

Country Link
US (2) US11773170B2 (fr)
EP (2) EP4553088A3 (fr)
JP (3) JP2020530028A (fr)
KR (1) KR20200042485A (fr)
CN (4) CN118580366A (fr)
AU (2) AU2018312816B2 (fr)
BR (1) BR112020002695A2 (fr)
CA (1) CA3072404A1 (fr)
DK (1) DK3665198T3 (fr)
EA (1) EA202090215A1 (fr)
ES (1) ES3025738T3 (fr)
FI (1) FI3665198T3 (fr)
HR (1) HRP20250474T2 (fr)
HU (1) HUE071182T2 (fr)
IL (1) IL272461A (fr)
LT (1) LT3665198T (fr)
MA (2) MA71419A (fr)
MD (1) MD3665198T3 (fr)
MX (1) MX2020001432A (fr)
PH (1) PH12020550055A1 (fr)
PL (1) PL3665198T3 (fr)
PT (1) PT3665198T (fr)
RS (1) RS66708B9 (fr)
SG (1) SG11202001050PA (fr)
SI (1) SI3665198T1 (fr)
TW (1) TWI874301B (fr)
WO (1) WO2019031965A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250157457A (ko) 2015-10-23 2025-11-04 메뤼스 엔.페. 암 성장을 억제하는 결합 분자
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
WO2018182422A1 (fr) 2017-03-31 2018-10-04 Merus N.V. Anticorps bispécifiques de liaison à l'erbb-2 et erbb-3 destinés à être utilisés dans le traitement des cellules (f) qui présentent un gène de fusion (nrg1)
MA52212A (fr) * 2018-03-30 2021-02-17 Merus Nv Anticorps multivalent
JP2022520632A (ja) * 2019-02-15 2022-03-31 インテグラル・モレキュラー・インコーポレイテッド 共通軽鎖を含む抗体及びその使用
CA3139402A1 (fr) 2019-05-09 2020-11-12 Merus N.V. Domaines variants pour la multimerisation de proteines et leur separation
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
CN112898427B (zh) * 2019-12-03 2023-06-30 同济大学苏州研究院 一种抗c-Met单臂抗体及其制备方法和应用
CN117480180A (zh) 2021-07-14 2024-01-30 江苏恒瑞医药股份有限公司 特异性结合hgfr和egfr的抗原结合分子及其医药用途
WO2023172133A1 (fr) 2022-03-07 2023-09-14 Merus N.V. Polythérapie comprenant des anticorps se liant à l'egfr et au cmet
IL315479A (en) * 2022-03-07 2024-11-01 Merus Nv Treatment with an antibody that binds EGFR and CMET
CN119487075A (zh) * 2022-06-29 2025-02-18 百奥赛图(北京)医药科技股份有限公司 抗egfr/met抗体及其用途
JP2025539837A (ja) 2022-11-24 2025-12-09 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 Ｈｇｆｒとｅｇｆｒに特異的に結合する二重特異性抗体を含む医薬組成物
WO2025025434A1 (fr) * 2023-08-02 2025-02-06 百泰生物药业有限公司 Anticorps bispécifique egfr/c-met et son utilisation
TW202540183A (zh) 2023-11-17 2025-10-16 荷蘭商美勒斯公司 包含將ＥＧＦＲ和ｃＭＥＴ結合的抗體的組合療法
WO2025230410A1 (fr) * 2024-04-30 2025-11-06 Merus N.V. Conjugués anticorps-médicament multispécifiques
WO2025230409A1 (fr) * 2024-04-30 2025-11-06 Merus N.V. Conjugués anticorps-médicament multispécifiques
WO2025247206A1 (fr) * 2024-05-27 2025-12-04 上海迈晋生物医药科技有限公司 Molécule de liaison à l'antigène se liant de manière spécifique à egfr et cmet, conjugué de médicament associé et utilisation médicale associée
CN121045388A (zh) * 2024-05-30 2025-12-02 英百瑞(杭州)生物医药有限公司 针对人c-Met和人EGFR的双特异性抗体及其用途
WO2025247330A1 (fr) * 2024-05-31 2025-12-04 江苏先声生物制药有限公司 Conjugué anticorps-médicament bispécifique anti-egfr × cmet et son utilisation

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
NZ226694A (en) 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
ES2199216T3 (es) 1991-07-15 2004-02-16 The Wellcome Foundation Limited Produccion de anticuerpos.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE29706518U1 (de) 1997-04-11 1997-05-22 E. Missel GmbH & Co., 70374 Stuttgart Trägersystem für Bade-, Dusch- oder Whirlwannen
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
ES2237420T5 (es) 1999-04-15 2010-03-03 Crucell Holland B.V. Produccion de proteina recombinante en una celula humana.
DE29915950U1 (de) 1999-09-10 1999-12-30 CMW Automation GmbH, 65594 Runkel Vorrichtung zum Elektrolytbefüllen der Zellen eines Akkumulators
US20070111201A1 (en) 2001-04-30 2007-05-17 Benjamin Doranz Reverse transfection of cell arrays for structural and functional analyses of proteins
ES2344070T3 (es) 2001-07-04 2010-08-17 Chromagenics B.V. Secuencias de adn con actividad anti-represora.
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US20050130224A1 (en) 2002-05-31 2005-06-16 Celestar Lexico- Sciences, Inc. Interaction predicting device
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
MXPA05006724A (es) 2003-01-07 2005-09-08 Symphogen As Metodo para producir proteinas policlonales recombinantes.
EP2322547A1 (fr) 2003-06-25 2011-05-18 Crucell Holland B.V. Lectin specifique de cellules myeloides
JP2007536254A (ja) 2004-05-05 2007-12-13 メリマック ファーマシューティカルズ インコーポレーティッド 生物活性を調節するための二重特異性結合剤
CA2569509C (fr) 2004-06-03 2014-08-12 Novimmune S.A. Anticorps anti-cd3 et leurs methodes d'utilisation
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1853309A4 (fr) 2005-02-23 2008-10-22 Merrimack Pharmaceuticals Inc Agents de liaison bispecifiques utilises pour moduler une activite biologique
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
EP2035456A1 (fr) 2006-06-22 2009-03-18 Novo Nordisk A/S Production d'anticorps bispécifiques
EP2059533B1 (fr) 2006-08-30 2012-11-14 Genentech, Inc. Anticorps multispécifiques
US8290739B2 (en) 2006-10-20 2012-10-16 Amfit, Inc. Method for determining relative mobility of regions of an object
US8580263B2 (en) 2006-11-21 2013-11-12 The Regents Of The University Of California Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
PL2129396T3 (pl) 2007-02-16 2014-02-28 Merrimack Pharmaceuticals Inc Przeciwciała przeciw ERBB3 i ich zastosowania
EP2139924B1 (fr) 2007-03-29 2016-07-06 Genmab A/S Anticorps bispécifiques et procédés de production de ceux-ci
AU2008234019B2 (en) 2007-04-03 2014-05-29 Amgen Research (Munich) Gmbh Cross-species-specific bispecific binders
US7705103B2 (en) 2007-06-22 2010-04-27 3M Innovative Properties Company Polydiorganosiloxane polyoxamide copolymers
EP3009148B1 (fr) 2007-07-02 2018-08-22 Oncomed Pharmaceuticals, Inc. Compositions et procédés de traitement et de diagnostic d'un cancer
EP2211903A4 (fr) 2007-10-17 2011-07-06 Nuvelo Inc Anticorps anti-cll-1
CA2711843C (fr) 2007-12-20 2018-11-13 Laboratory Corporation Of America Holdings Procedes de diagnostic du her-2
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
EP2245571B1 (fr) 2008-02-05 2019-04-10 Zymeworks Inc. Procédés de détermination de résidus corrélés dans une protéine ou autre biopolymère mettant en uvre la dynamique moléculaire
PT3456190T (pt) 2008-06-27 2022-02-15 Merus Nv Animal murino transgénico produtor de anticorpo
CN102137874B (zh) 2008-08-29 2015-02-18 西福根有限公司 抗表皮生长因子受体的重组抗体组合物
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
CN104262483A (zh) 2009-01-26 2015-01-07 根马布股份公司 用于生成抗体混合物的方法
NZ594665A (en) 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
KR101747103B1 (ko) 2009-06-26 2017-06-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
SG178509A1 (en) 2009-08-21 2012-04-27 Merrimack Pharmaceuticals Inc Antibodies against the ectodomain of erbb3 and uses thereof
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
JP5960598B2 (ja) 2009-11-04 2016-08-02 アフィボディ・アーベー Ｈｅｒ３結合ポリペプチド
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US10143186B2 (en) 2010-02-08 2018-12-04 Regeneron Pharmaceuticals, Inc. Common light chain mouse
CA2797981C (fr) 2010-05-14 2019-04-23 Rinat Neuroscience Corporation Proteines heterodimeriques et leurs procedes de production et de purification
RU2608640C2 (ru) 2010-08-16 2017-01-23 Новиммун С.А. Способы получения мультиспецифичных и мультивалентных антител
PL2606070T3 (pl) 2010-08-20 2017-06-30 Novartis Ag Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
WO2012116317A2 (fr) 2011-02-24 2012-08-30 Merrimack Pharmaceuticals, Inc. Polythérapies comprenant des agents anti-erbb3
AU2012229147B2 (en) 2011-03-11 2015-12-24 Merrimack Pharmaceuticals, Inc. Use of inhibitors of EGFR-family receptors in the treatment of hormone refractory breast cancers
US20150231238A1 (en) 2011-03-15 2015-08-20 Merrimack Pharmaceuticals, Inc. Overcoming resistance to erbb pathway inhibitors
US9683052B2 (en) 2011-03-25 2017-06-20 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
GB201106395D0 (en) 2011-04-14 2011-06-01 Hubrecht Inst Compounds
WO2012156309A1 (fr) 2011-05-13 2012-11-22 Millegen Anticorps contre her3
AU2012274461A1 (en) 2011-06-20 2014-01-16 Kyowa Hakko Kirin Co., Ltd. Anti-erbB3 antibody
EP3401329A1 (fr) 2011-07-15 2018-11-14 OncoMed Pharmaceuticals, Inc. Agents de fixation aux protéines rspo et leurs utilisations
US9567827B2 (en) 2013-07-15 2017-02-14 Downhole Technology, Llc Downhole tool and method of use
CA2791109C (fr) 2011-09-26 2021-02-16 Merus B.V. Generation de molecules de liaison
CA2849508C (fr) 2011-09-30 2020-12-22 Regeneron Pharmaceuticals, Inc. Anticorps anti-erbb3 et leurs utilisations
AU2012340766B2 (en) 2011-11-23 2018-05-10 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
MX2014006731A (es) 2011-12-05 2015-06-04 Novartis Ag Anticuerpos para el receptor del factor de crecimiento epidermico 3 (her3) dirigidos al dominio iii y al dominio iv del her3.
AU2012349735B2 (en) 2011-12-05 2016-05-19 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
CN102448183A (zh) 2012-01-18 2012-05-09 大唐移动通信设备有限公司 一种Uu接口重配置方法及设备
WO2013134686A1 (fr) 2012-03-09 2013-09-12 Promega Corporation Détecteurs de ph
WO2013148315A1 (fr) 2012-03-27 2013-10-03 Genentech, Inc. Diagnostic et traitements concernant des inhibiteurs de her3
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
DK2838917T3 (da) 2012-04-20 2019-08-26 Merus Nv Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
TW201843172A (zh) * 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
HRP20181717T1 (hr) 2012-09-27 2018-12-28 Merus N.V. Bispecifična igg protutijela kao aktivatori t stanice
JP2015532306A (ja) 2012-10-15 2015-11-09 チューリッヒ大学 癌治療のための二重特異性ｈｅｒ２リガンド
AU2013347962B2 (en) * 2012-11-21 2018-10-25 Janssen Biotech, Inc. Bispecific EGFR/c-Met antibodies
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
WO2014159580A1 (fr) 2013-03-14 2014-10-02 Oncomed Pharmaceuticals, Inc. Agents de liaison à la protéine c-met et leurs utilisations
CN105264382A (zh) 2013-04-05 2016-01-20 美国控股实验室公司 基于检测her3活化辅助癌症的诊断、预后和治疗的系统和方法
JP2016520586A (ja) 2013-05-08 2016-07-14 ザイムワークス，インコーポレイテッド 二重特異性ｈｅｒ２およびｈｅｒ３抗原結合性構築物
WO2014197854A1 (fr) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Nouveaux lieurs pour conjugués anticorps-médicament et composés connexes, compositions, et procédés d'utilisation
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
US10208354B2 (en) 2013-08-07 2019-02-19 Universität Zu Köln NRG1 fusion genes in cancer
US9551208B2 (en) 2013-08-26 2017-01-24 Halliburton Energy Services, Inc. Identifying uncertainty associated with a stimulated reservoir volume (SRV) calculation
WO2015066543A1 (fr) 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Ciblage de her2 et her3 avec des anticorps bispécifiques dans des cellules cancéreuses
HRP20250041T1 (hr) 2014-02-28 2025-03-14 Merus N.V. Antitijelo koje veže erbb-2 i erbb-3
ES2816624T3 (es) 2014-02-28 2021-04-05 Merus Nv Anticuerpos que se unen a EGFR y ERBB3
RS59077B1 (sr) 2014-03-11 2019-09-30 Regeneron Pharma Anti-egfrviii antitela i njihova primena
AU2015240599B2 (en) 2014-04-04 2020-11-19 Bionomics, Inc. Humanized antibodies that bind LGR5
WO2016077734A2 (fr) 2014-11-14 2016-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cellules nk présentant une toxicité cellulaire dépendante des anticorps accrue contre les tumeurs
MA41123A (fr) 2014-12-02 2017-10-10 Oncomed Pharm Inc Polythérapie pour le traitement du cancer
ES2693596T3 (es) 2015-07-10 2018-12-12 Merus N.V. Anticuerpo que se une a CD3 humano
TWI784917B (zh) * 2015-09-23 2022-11-21 美商再生元醫藥公司 最優化抗ｃｄ３雙特異性抗體及其用途
KR20250157457A (ko) * 2015-10-23 2025-11-04 메뤼스 엔.페. 암 성장을 억제하는 결합 분자
WO2018182422A1 (fr) 2017-03-31 2018-10-04 Merus N.V. Anticorps bispécifiques de liaison à l'erbb-2 et erbb-3 destinés à être utilisés dans le traitement des cellules (f) qui présentent un gène de fusion (nrg1)

Also Published As

Publication number Publication date
PH12020550055A1 (en) 2020-10-19
HRP20250474T1 (hr) 2025-06-06
ES3025738T3 (en) 2025-06-09
EP3665198B1 (fr) 2025-01-22
BR112020002695A2 (pt) 2020-08-25
WO2019031965A1 (fr) 2019-02-14
EP3665198A1 (fr) 2020-06-17
JP7736772B2 (ja) 2025-09-09
HUE071182T2 (hu) 2025-08-28
EA202090215A1 (ru) 2020-07-01
PL3665198T3 (pl) 2025-06-09
RS66708B9 (sr) 2025-08-29
KR20200042485A (ko) 2020-04-23
PT3665198T (pt) 2025-05-02
AU2021202874B2 (en) 2024-10-10
CN111094351A (zh) 2020-05-01
MA49846A (fr) 2020-06-17
US20240174756A1 (en) 2024-05-30
EP4553088A2 (fr) 2025-05-14
EP4553088A3 (fr) 2025-12-31
US11773170B2 (en) 2023-10-03
TW201910354A (zh) 2019-03-16
SI3665198T1 (sl) 2025-06-30
AU2021202874A1 (en) 2021-06-03
FI3665198T3 (fi) 2025-04-25
HRP20250474T2 (hr) 2025-08-01
CN111094351B (zh) 2024-07-12
TWI874301B (zh) 2025-03-01
AU2018312816A1 (en) 2020-02-27
AU2018312816B2 (en) 2021-05-27
MD3665198T2 (ro) 2025-07-31
US20200247892A1 (en) 2020-08-06
LT3665198T (lt) 2025-05-26
MD3665198T3 (ro) 2025-08-31
RS66708B1 (sr) 2025-05-30
DK3665198T3 (da) 2025-04-28
CA3072404A1 (fr) 2019-02-14
ES3025738T9 (en) 2025-07-10
SG11202001050PA (en) 2020-03-30
CN118562014A (zh) 2024-08-30
JP2020530028A (ja) 2020-10-15
CN118580366A (zh) 2024-09-03
MX2020001432A (es) 2020-03-20
FI3665198T9 (fi) 2025-07-02
JP2024029049A (ja) 2024-03-05
CN119119283A (zh) 2024-12-13
JP2025176063A (ja) 2025-12-03
MA71419A (fr) 2025-04-30
IL272461A (en) 2020-03-31
EP3665198B9 (fr) 2025-05-21

Similar Documents

Publication Publication Date Title
MA49846B1 (fr) Anticorps liant egfr et cmet
JOP20210304A1 (ar) علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
CR11030A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos, que se unen especificamente a cd154 y sus usos
MA58293B1 (fr) Molécules de liaison pd-1 et leurs procédés d'utilisation
CR20230263A (es) Anticuerpos anti-hla-g y uso de estos
WO2018217940A3 (fr) Anticorps bispécifiques anti-pd-1/lag3, compositions de ceux-ci et procédés de fabrication et d'utilisation de ceux-ci
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
AR099812A1 (es) Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
EA202090718A1 (ru) Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1)
EP2497783A3 (fr) Protéines de liaison avec l'antigène du facteur de croissance de type facteur de croissance épidermique se liant à l'héparine
PE20091196A1 (es) Anticuerpos contra el vegf completamente humano, composiciones y metodos
CY1118668T1 (el) Ανοσοσυζευγματα εναντι υποδοχεα φολικου οξεος 1 και χρησεις αυτων
WO2018218056A8 (fr) Anticorps comprenant des régions constantes de chaîne lourde modifiées
PL406852A1 (pl) Preparat zawierający ludzkie przeciwciała do leczenia zaburzeń związanych z TNF-α
WO2010054265A3 (fr) Anticorps monoclonaux anti-récepteur 2 du facteur de croissance des fibroblastes
PE20200695A1 (es) Anticuerpos que reconocen tau
PE20091845A1 (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2019005639A3 (fr) Anticorps multispécifiques et procédés de préparation et d'utilisation associés
WO2011002968A3 (fr) Polypeptides et procédé de traitement
WO2020086406A3 (fr) Anticorps anti-npr1 et leurs utilisations
HK1250736A1 (zh) 用三种完全人类单克隆抗egfr抗体的组合治疗具有表皮生长因子受体(egfr)的胞外结构域的突变的患者的方法
WO2021048564A3 (fr) Domaine de liaison à l'antigène
WO2020106461A3 (fr) Anticorps anti-mertk et leurs méthodes d'utilisation
EP3947689A4 (fr) Agents de liaison à l'antigène se liant spécifiquement à la variante iii du récepteur du facteur de croissance épidermique
EP2287194A3 (fr) Anticorps anti-ephb4 pour inhiber l'angiogénèse et la croissance tumorale